{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:11:40Z","timestamp":1770919900141,"version":"3.50.1"},"reference-count":119,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Multiple myeloma is characterized by a wide clinical heterogeneity due to an intricate network of interactions between bone marrow-resident clonal plasma cells and the microenvironment. Over the last years, dramatic improvement in the understanding of these pathways led to the introduction of novel drugs with immune-mediated mechanisms of action. Some of these compounds, such as the anti-cd38 daratumumab and isatuximab, the anti-slamf-7 elotuzumab, and the antibody-drug conjugate belantamab-mafodotin, have been tested in large clinical trials and have now fully entered the real-life management. The bispecific T-cell engagers are under investigation with promising results, and other satisfactory data is expected from the application of nanotechnologies. The perfect timing to introduce these drugs in the sequence of treatment and their adverse events represent new challenges to be addressed, and further experience is required to improve their use.<\/jats:p>","DOI":"10.3390\/biom12081146","type":"journal-article","created":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T21:05:51Z","timestamp":1661115951000},"page":"1146","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment"],"prefix":"10.3390","volume":"12","author":[{"given":"Gianfranco","family":"Lapietra","sequence":"first","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Fazio","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0688-4882","authenticated-orcid":false,"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/leu.2015.33","article-title":"Early mortality in multiple myeloma","volume":"29","author":"Costa","year":"2015","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma\u2014An IMWG Research Project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: A target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood-2013-02-483511","article-title":"Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity","volume":"122","author":"Cagnetta","year":"2013","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fimmu.2017.00305","article-title":"Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche","volume":"8","author":"Chillemi","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/0008-5472.CAN-18-0773","article-title":"CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma","volume":"79","author":"Marlein","year":"2019","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance","volume":"9","author":"Usmani","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","article-title":"CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma","volume":"88","author":"Veillette","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-drug conjugates: Future directions in clinical and translational strategies to improve the therapeutic index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies","volume":"1","author":"Bakker","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2016-07-726729","article-title":"Phase \u00bd study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"128","author":"Plesner","year":"2016","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_22","unstructured":"Mateos, M.V., Moreau, P., Comenzo, R., Blad\u00e9, J., Benboubker, L., de la Rubia, J., Facon, T., Fay, J., Qin, X., and Masterson, T. (2015, January 11\u201314). An open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma. Proceedings of the 20th Congress of the European Hematology Association, Vienna, Austria."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Nahi, H., Chrobok, M., Gran, C., Lund, J., Gruber, A., Gahrton, G., Ljungman, P., Wagner, A.K., and Alici, E. (2019). Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211927"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Agents targeting lymphoid Multiple Myeloma 16 or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1016\/j.clml.2020.04.004","article-title":"Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma","volume":"20","author":"Kamble","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103623","DOI":"10.1016\/j.critrevonc.2022.103623","article-title":"Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel","volume":"172","author":"Girmenia","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2017-0328","article-title":"EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma","volume":"23","author":"Tzogani","year":"2018","journal-title":"Oncologist"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1373\/clinchem.2010.152116","article-title":"Interference of monoclonal antibody therapies with serum protein electrophoresis tests","volume":"56","author":"McCudden","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","article-title":"Monitoring multiple myeloma patients treated with daratumumab: Teasing out monoclonal antibody interference","volume":"54","author":"McCudden","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1021\/acs.analchem.0c03357","article-title":"High-Throughput Therapeutic Antibody Interference-Free High-Resolution Mass Spectrometry Assay for Monitoring M-Proteins in Multiple Myeloma","volume":"93","author":"Santockyte","year":"2021","journal-title":"Anal. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1515\/cclm-2021-0399","article-title":"Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: The laboratory solution to eliminate interference","volume":"59","author":"Noori","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Plesner, T., van de Donk, N., and Richardson, P.G. (2020). Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. Cells, 9.","DOI":"10.3390\/cells9020378"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41375-019-0536-3","article-title":"In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab","volume":"34","author":"Atanackovic","year":"2020","journal-title":"Leukemia"},{"key":"ref_41","unstructured":"Sanof-Aventis (2021, April 22). SARCLISA (Isatuximab): EU Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/bjh.17499","article-title":"Subgroup analysis of ICARIA-MM study in relapsed\/refractory multiple myeloma patients with high-risk cytogenetics","volume":"194","author":"Harrison","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carflzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood.2020008209","article-title":"Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Dimopoulos","year":"2021","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood.V126.23.3015.3015","article-title":"MOR202, a human anti-CD38 monoclonal antibody, mediates potent tumoricidal activity in vivo and shows synergistic efficacy in combination with different antineoplastic compounds","volume":"126","author":"Boxhammer","year":"2015","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3026(19)30249-2","article-title":"MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: A first-in-human, multicentre, phase 1-2a trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"Szmania","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: Final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/bjh.14263","article-title":"Elotuzumab in combination with thalidomide and low-dose dexamethasone: A phase 2 single-arm safety study in patients with relapsed\/refractory multiple myeloma","volume":"175","author":"Mateos","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: Final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12185-019-02757-0","article-title":"Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A randomized, open-label, phase 2 study in Japan","volume":"111","author":"Kubo","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): An open-label, multicentre, randomised, phase 3 trial","volume":"9","author":"Dimopoulos","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo","volume":"20","author":"Alavi","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1200\/JCO.2020.38.15_suppl.8502","article-title":"DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib\/dexamethasone in relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Nooka","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2217\/fon-2020-1269","article-title":"Belantamab mafodotin in combination with novel agents in relapsed\/refractory multiple myeloma: DREAMM-5 study design","volume":"17","author":"Nooka","year":"2021","journal-title":"Future Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"E154","DOI":"10.1016\/j.clml.2019.09.257","article-title":"MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma","volume":"19","author":"Xing","year":"2019","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-136375","article-title":"Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood-2018-99-118412","article-title":"HDP101, a novel B-Cell Maturation Antigen (BCMA)-targeted antibody conjugated to \u03b1-Amanitin, is active against myeloma with preferential efficacy against pre-clinical models of deletion 17p","volume":"132","author":"Singh","year":"2018","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A phase 1 First in Human (FIH) study of AMG 701, an anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule, in Relapsed\/Refractory (RR) Multiple Myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2021-144921","article-title":"Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"138","author":"Zonder","year":"2021","journal-title":"Blood"},{"key":"ref_80","first-page":"S205","article-title":"Interim results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) 2+1 T-cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"295025","author":"Costa","year":"2020","journal-title":"EHA Libr."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood-2021-152984","article-title":"MagnetisMM-3: An open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma","volume":"138","author":"Lesokhin","year":"2021","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2021-150757","article-title":"A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 Bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: State of the art and prospects","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Dietrich","year":"2021","journal-title":"Nat. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2021-146868","article-title":"Updated phase 1 results from MonumenTAL-1: First-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Krishnan","year":"2021","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and\/or Refractory Multiple Myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/gtmb.2015.0169","article-title":"Association of IL-6 Promoter and Receptor Polymorphisms with Multiple Myeloma Risk: A Systematic Review and Meta-Analysis","volume":"20","author":"Li","year":"2016","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Desantis, V., Savino, F.D., Scaringella, A., Potenza, M.A., Nacci, C., Frassanito, M.A., Vacca, A., and Montagnani, M. (2022). The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092513"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-8958-4_1","article-title":"Human Monoclonal Antibodies: The Benefits of Humanization","volume":"1904","author":"Waldmann","year":"2019","journal-title":"Methods Mol Biol."},{"key":"ref_99","first-page":"33","article-title":"Monoclonal antibody therapy of solid tumors: Clinical limitations and novel strategies to enhance treatment efficacy","volume":"13","author":"Cruz","year":"2019","journal-title":"Biologics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The Therapeutic Potential of Nanobodies","volume":"34","author":"Muyldermans","year":"2020","journal-title":"BioDrugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"632687","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity Risk Profile of Nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.1039\/D2NR00306F","article-title":"Nanobodies: From structure to applications in non-injectable and bispecific biotherapeutic development","volume":"14","author":"Li","year":"2022","journal-title":"Nanoscale"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-0716-2075-5_7","article-title":"Cytoplasmic Production of Nanobodies and Nanobody-Based Reagents by Co-Expression of Sulfhydryl Oxidase and DsbC Isomerase","volume":"2446","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1158\/1535-7163.MCT-21-0220","article-title":"The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy","volume":"21","author":"Puttemans","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.120.251983","article-title":"Comparison of CD38-Targeted \u03b1- Versus \u03b2-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model","volume":"62","author":"Minnix","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2000699","DOI":"10.1080\/2162402X.2021.2000699","article-title":"CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma","volume":"10","author":"Puttemans","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood.2021013794","article-title":"Redefining nonmeasurable multiple myeloma using mass spectrometry","volume":"139","author":"Giles","year":"2022","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41375-019-0540-7","article-title":"BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: Clinical applications","volume":"34","author":"Bae","year":"2020","journal-title":"Leukemia"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Nigro, A., Frattaruolo, L., Fava, M., De Napoli, I., Greco, M., Comand\u00e8, A., De Santo, M., Pellegrino, M., Ricci, E., and Giordano, F. (2020). Bortezomib-Loaded Mesoporous Silica Nanoparticles Selectively Alter Metabolism and Induce Death in Multiple Myeloma Cells. Cancers, 12.","DOI":"10.3390\/cancers12092709"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","article-title":"Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma","volume":"11","author":"Federico","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00262-018-2181-5","article-title":"Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies","volume":"67","author":"Harwood","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s42003-020-01515-x","article-title":"Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum","volume":"3","author":"Olsen","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1007\/s13277-014-1920-2","article-title":"Aptamer TY04 inhibits the growth of multiple myeloma cells via cell cycle arrest","volume":"35","author":"Dai","year":"2014","journal-title":"Tumour. Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.biochi.2018.06.003","article-title":"Screening and characterization of an Annexin A2 binding aptamer that inhibits the proliferation of myeloma cells","volume":"151","author":"Zhou","year":"2018","journal-title":"Biochimie"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1111\/jcmm.13870","article-title":"Targeting c-met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma","volume":"22","author":"Zhang","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.omtn.2019.10.021","article-title":"An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery","volume":"18","author":"Catuogno","year":"2019","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Schavgoulidze, A., Cazaubiel, T., Perrot, A., Avet-Loiseau, H., and Corre, J. (2021). Multiple Myeloma: Heterogeneous in Every Way. Cancers, 13.","DOI":"10.3390\/cancers13061285"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41375-021-01422-y","article-title":"Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression","volume":"36","author":"Dahlhoff","year":"2022","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3389\/fimmu.2020.02153","article-title":"Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells","volume":"11","author":"Cooke","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/8\/1146\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:12:33Z","timestamp":1760141553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/8\/1146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":119,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["biom12081146"],"URL":"https:\/\/doi.org\/10.3390\/biom12081146","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]}}}